SCHEMBL1267690

SCHEMBL1267690

CSC(=S)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
ALDH1A1 P00352 6/20 0.52
IDO1 P14902 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
TSHR P16473 2/20 0.43
RAB9A P51151 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
LMNA P02545 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7642817 0.84 TSHR (0.45) CA12CA1CA2CA9ALDH1A1
SCHEMBL23250879 0.83 NAAA (0.46) CA12CA1CA2CA9ALDH1A1
SCHEMBL17765046 0.83 NAAA (0.46) CA12CA1CA2CA9ALDH1A1
SCHEMBL6102145 0.81 IDO1 (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL29694804 0.81 SLC6A4 (0.40) IDO1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL22732123 0.81 IDO1 (0.44) ALDH1A1IDO1L3MBTL1KMT2ARAB9A
SCHEMBL22732283 0.81 MEN1 (0.44) ALDH1A1IDO1L3MBTL1KMT2AMAPK1
SCHEMBL816466 0.80 L3MBTL1 (0.48) CA12CA1CA2CA9ALDH1A1
SCHEMBL12392478 0.80 L3MBTL1 (0.48) CA12CA1CA2CA9ALDH1A1
SCHEMBL865387 0.78 CA12 (0.53) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4263672-B1 SELF-BLOWING ISOCYANATE-FREE POLYURETHANE FOAMS UNIV LIEGE (BE) 2024-10-09 EP disclosed
US-20230416487-A1 SELF-BLOWING ISOCYANATE-FREE POLYURETHANE FOAMS Université de Liège (BE) 2023-12-28 US disclosed
EP-4263672-A1 SELF-BLOWING ISOCYANATE-FREE POLYURETHANE FOAMS Université de Liège (BE) 2023-10-25 EP disclosed
WO-2022128822-A1 SELF-BLOWING ISOCYANATE-FREE POLYURETHANE FOAMS Université de Liège (BE) 2022-06-23 WO disclosed
EP-4015563-A1 SELF-BLOWING ISOCYANATE-FREE POLYURETHANE FOAMS Université de Liège (BE) 2022-06-22 EP disclosed
US-8324176-B2 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-12-04 US disclosed
US-8324176-B2 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-12-04 US disclosed
US-7888487-B2 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-02-15 US disclosed
EP-1364958-B1 GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2010-09-08 EP disclosed
EP-1364958-B1 GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2010-09-08 EP disclosed
US-7375087-B2 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-05-20 US disclosed
US-7294618-B2 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-11-13 US disclosed
US-7294618-B2 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-11-13 US disclosed
US-7294618-B2 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-11-13 US disclosed
US-7217697-B2 Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-05-15 US disclosed
US-20060128635-A1 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2006-06-15 US disclosed
EP-1550668-A1 PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2005-07-06 EP disclosed
US-20040116357-A1 For prophylaxis and therapy of hyperglycemia such as diabetes, diabetic complications or obesity KISSEI PHARMACEUTICAL CO., LTD. (JP) 2004-06-17 US disclosed
EP-1364958-A1 GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2003-11-26 EP disclosed
US-4569797-A REACTING CARBONYL SULFIDE WITH METAL MERCAPTIDE IN APROTIC SOLVENT VIRGINIA CHEMICALS INC. (US) 1986-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128635-A1 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same SLC2A3, SLC2A1, SLC5A1 CA12 3140/4885CA1 3104/4885CA2 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.